Page 7 - Array Biopharma News Today

Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.

Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).

Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

Anixa Biosciences (NASDAQ:ANIX – Get Rating) and ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares Anixa Biosciences and […]

First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanomaA global partnership between EORTC and

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

Survival rates have increased for many cancers over the past two decades, but there remains an unmet need for more effective therapies. This article...

Survival rates have increased for many cancers over the past two decades, but there remains an unmet need for more effective therapies. This article...

A BRAF-MEK inhibitors are a chemical or drug that restricts the mitogen-activated protein kinase and kinase, enzymes MEK1 and/or MEK2. The chemicals are used to affect the BRAF-MEK pathway which is often overactive in some cancers. Hence, the BRAF-MEK inhibitors have potential for treatment of some cancers, especial...

The current understanding of Chronic Spontaneous Urticaria has greatly improved in recent decades, leading to rising awareness, improved management, better...